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Introduction
β-Glucans are composed of repeating glucose 
monomer units linked by β-1,3-glycosidic bonds 
(Yamada et al.,2009). Moreover, fungi have a β-Glucan 
rich cell wall compromised of glucose residues arranged 
in β (1–3) D glucopyranosyl polymers and β (1–6) D 
glucopyra-nosyl side chains with varying length and 
frequency distribution (Lebron et al., 2003). However, beta 
glucans, which are isolated from different sources exhibited 
different structures and solubility, but interestingly, they 
have similar biological properties (Sawai et al., 2002). 
Several  investigations in animals and humans have 
subsequently shown that β-glucans, either particulate or 
soluble, represent immune stimulating properties, including 
anti-bacterial and anti-tumor activities through different 
pathways like activation of immune cells to suppress 
cancer cell proliferation (Choromanska et al., 2018; Sima 
et al., 2019; Vetvicka et al., 1996). The existence of special 
membrane receptors on leukocytes for β-glucan mediate 
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immunomodulating function. β-glucans primarily  activate 
innate immune system such as macrophage, Dendritic cells 
and secretion pro-inflamatory cytokines, subsequently 
activation  adaptive immune cells specifically various  T 
cells subtypes in tumor micro environment, ultimately 
destruct  tumor cells,leading to  cell death. (Herre et al., 
2004; Schorey et al., 2008; Taylor et al., 2002).
Mesenchymal stem cells (MSCs) are fibroblast-like 
cells and they can be easily isolated from bone marrow, 
adipose, and other tissues including cord blood, peripheral 
blood, fetal liver, skeletal muscle, placenta, amniotic fluid 
and synovium (Campagnoli et al., 2001, Scherjon et al., 
2003; Zuk et al., 2002; Erices et al., 2001; De Bari et 
al., 2002; Kuznetsov et al., 2001;Tondreau et al., 2005). 
In other words, MSCs are a subset of non-hematopoietic 
adult stem cells that originate from the mesoderm. 
They possess self-renewal ability and multi-lineage 
differentiation into not only mesoderm lineages, such 
as chondrocytes, osteocytes and adipocytes, but also 
ectodermic cells and endodermic cells (Wei et al., 2013).
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Recently, laboratory and clinical data on the use of 
MSCs have fueled an increasing interest in diverse fields, 
especially for cancer. So that, MSCs can also suppress tumor 
growth by cell cycle arrest and inhibition of proliferation. 
Anti-tumor properties are described for MSCs isolated 
from various sources in experiments both in vitro and in 
vivo of various tumors. To date, there are large number 
of experimental studies that confirm the anti-oncogenic 
potential of MSCs modified with therapeutic genes and/
or loaded with chemotherapeutic drugs (Chulpanova et 
al., 2018). Nonetheless, it has been shown that MSCs can 
also home to tumor sites and contributes to tumor growth 
and progression. It is not obvious however, whether 
the MSC effect is predominantly tumor promoting or 
suppressive (Ridge et al., 2017). However, MSC have 
immune modulating properties that mostly suppress the 
immune response by production of inhibitory mediators 
such as IDO, TGF- β, PGE-2 and IL-10.
Lung cancer is the most common cancer in terms of 
both incidence and cancer-related mortality worldwide 
(Roudi et al., 2017). 
 Although significant progress has been made in the 
understanding of disease pathogenesis and development of 
novel therapies, lung cancer remains an incurable disease. 
Lung cancer is a heterogeneous disease categorized into 
two main types: small-cell lung cancer (SCLC) and non-
small-cell lung cancer (NSCLC) (Liu et al.,2014). Until 
now few clinical trial for beta-glucans in lung cancer 
patient was carried out and continued (Weitberg et al., 
2008; Gao et al., 2005). However, the anti-cancer activity 
of beta-glucans against cancer cells was shown in the 
previous published data but the efficacy of this component 
have not been reported on MSCs until now, to raise this 
issue, in the current study, we sought for the first time to 
assess the effect of beta glucan extracted from C. albicans 
cell wall on MSC cells for the induction of apoptosis, in 
vitro (Roudi et.al.,2017) and (Geller et.al.2019).
Materials and Methods
β (1,3) Glucan extraction of Candida albicans Cell wall 
and characterization 
β-glucan was extracted from C. albicans cell wall 
(ATCC-10231) as previously described by (Nasrollahi et 
al., 2013) with some modifications. Solubilized β-glucans 
were obtained by oxidation of the Candida cell wall 
with sodium hypochlorite and sodium hydroxide (SDA, 
Merck). The particles solubilized by treatment with 
dimethyl sulfoxide (DMSO) (sigma) and zymolyase 
(sigma) digestion to extract β (1,3) D-glucan (20 mg 
beta glucan suspended in 10 mL of acetate buffer (50 
mM, pH 6.0) was mixed with 1 mg of Zymolyase 100T 
enzyme and also parentheses. The soluble fractions were 
lyophilized. Proton magnetic resonance (H NMR) was 
used to examine the extracted beta-glucan. The sample 
was dissolved in Deuterium oxide (D2O) (sigma) and 
NMR spectrum was recorded on a Bruker AVANCE 300 
FT-NMR spectrometer, resonating at 300 MHz (1 H) and 
compared with the 1H NMR spectrum of standard form 
of beta glucan. 
Cell Line
A549 cell line (Lung Adenoma carcinoma cells) 
was purchased from National Center for Genetic and 
Biological Reserves of Iran. The cells cultured on high 
glucose Dulbecco’s modified Eagle’s medium (DMEM, 
Gibco, USA) containing 10% fetal bovine serum (FBS) 
(Gibco, USA) in a humidified 37°C incubator with 5% 
CO2.
Isolation of mesenchymal stem cells
Adipose tissue was isolated from patients undergoing 
surgery. The adipose tissue was washed three times with PBS 
(Gibco, USA) buffer composed of penicillin/streptomycin 
(Gibco, USA) and digest by collagenase type 4 for 30 
hours at 37°C. After passing through 0.7 micron filter 
and removing the portion containing RBC, the cells were 
cultured in DMEM medium (Gibco, USA) containing 10% 
FBS (Gibco, USA), 1% Penicillin and Streptomycin and 
200mM  sterile-filtered L-Glutamine (Gibco, USA). MSCs 
passaged two and three times and were used for tests.
Characterization of MSC
Primary MSCs were isolated from human abdominal 
fat (5-10g) using collagenase-H, cultured for 3 weeks in 
advanced MEM medium (Gibco, USA) supplemented 
with platelet lysate (PLTmax, Mill Creek Life Sciences, 
Rochester, MN), and used at the third passage, as 
previously shown. Cells were characterized in vitro by 
flow cytometry analysis for CD45, CD11b, CD90, and 
CD105 using FACS Calibur (Becton, Dickinson and 
Company, Franklin Lakes, NJ) as previously described 
(Campagnoli et al., 2001; De Bari  et al., 2002). 
Osteogenic differentiation
The MSCs were trypsinized, counted and reseeded at 
5,000 cells/cm2 culture flask. The medium was replaced 
with osteo¬genic medium (low-glucose DMEM containing 
5% FBS, 10 nM dexamethasone, 50 μM L-ascorbic acid-
2-phosphate and 10 mM glycerophosphate; (all from 
Sigma-Aldrich) and cells incubated at 37oC in a humidified 
5% CO2 atmosphere. After 21 days, mineralization was 
measured using Alizarin Red S (Sigma) staining. Briefly, 
the MSC cultures were fixed in a 4% paraformaldehyde 
solution and stained with a 0.5% Alizarin Red (Sigma) 
solution.
Adipogenic differentiation
The MSCs were  seeded in  T-75 f lask  a t 
a concentration of 5,000 cells/cm2 and cultured in 
high-glucose DMEM supplemented with 10% FBS, 
1% penicillin-streptomycin, 10 μg/ml insulin, 1 μM 
dexamethasone and 0.5 mM 3-isobutyl-1-methylxanthine 
(IBMX; all from Sigma-Aldrich) at 37oC in a humidified 
5% CO2 atmosphere. After 14 days, the MSCs were stained 
using Oil Red O. Briefly, the cells were fixed with 10% 
formalin, washed with 60% isopropyl alcohol and stained 
with 2% Oil Red O reagent (Sigma-Aldtich). The staining 
was quantified by extracting the Oil Red O stain with 100% 
isopropyl alcohol. The incidence of cell differentiation was 
investigated and photographed by inverted microscope.
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USA) and presented as the mean ± SD from at least three 
independent experiments. Differences between groups 
were analyzed by an ANOVA; means of groups were 
compared by a t-test. P < 0.05 was considered statistically 
significant.
Results
Extraction  and characterization of β-glucans
Particulate β-glucan was extracted from C.albicans 
cell wall using a combination of acid and alkaline solution. 
Then, the structure of β-glucan was identified with NMR. 
The results are shown in Figure 1.
MSCs morphology
The cultures were observed daily by phase contrast 
invert microscopy to examine adherent cell morphology. 
In the early days, individual adherent cells appeared in 
about 30% of the flasks and 70% of the flasks having no 
adherent cells. During the second week, the number of 
floating cell decreased within the culture medium. By the 
end of week 3, these cells had been completely grown and 
the cells were expanded by several subcultures in 25 cm2 
flasks, and the passage-3 were used for future examination 
(Figure 2). 
Characterization of MSCs 
The MSCs were successfully and rapidly expanded into 
colonies of confluent spindle-shaped cells. The results of 
flow cytometry for CD45, CD11b , CD105 and CD90 
revealed that the cells were negative for CD11b (2.13%), 
CD45 (1.44%) and positive for CD105 (85.39%), CD90 
(94.00%). The cultured cells were considered MSCs 
(Figure 3).
Cytotoxicity evaluation of beta glucan on MSCs 
MSC proliferation and viability were determined 
by MTT (3-[4,5-Dimethyl-2 thiazoyl]-2,5-diphenyl-2 
Htetrazolium bromide) assay (Roudbary et al., 2013). 
For this, cells were cultured in 96-well microplates at 
a density of 104 cells/well. Twenty-four hours after the 
initial seeding, cells were either treated with extracted β 
(1,3) Glucan from the cell wall of Candida albicans in 
different concentration (2, 4, 8,10, 25, 50, 100, 200, 400, 
800 and 1,000 μg/ml) and incubated for 48 hrs. (MSCs 
were culture as triplicate wells with the final volume of 
100 μl/well). Then, all of the medium was removed and 
10μl of MTT solution (0.5mg/ml,Sigma) and 100 μl fresh 
medium without FBS added to each well. After incubation 
for 4h at 37°C, 100 μl DMSO (Sigma) was added to each 
well. After incubation for 15 minutes at room temperature 
under smooth agitation, the plate was read immediately 
and the absorbance of each well was measured by ELISA 
reader at wavelength of 570 nm. The average values for 
the blank was subtracted from the average values from 
triplicate readings of treated wells. The experiments 
were repeated three times and the results of which are 
presented as means.
Treatment of MSCs with optimal concentration of β (1,3) 
Glucan and supernatant collection
Third subculture of MSCs were seeded at 6× 104 cells 
per well into 6-well cell culture plates and after 24 hours 
treated with optimal beta-glucan concentration. For this, 
cell culture medium was removed and 200 μl of extracted 
beta-glucan and 600μl of complete culture medium was 
added to each well for 48 hours. Afterwards, supernatant 
medium was aspirated and centrifuged at 300 g for 10 
minutes to remove cellular debris and stored at -80°C 
for fur-ther assays.
Apoptosis assay
Apoptosis kit (FITC Annexin V Apoptosis Detection 
Kit I, BD Biosciences, and USA) was used to detect 
apoptotic cells. The manual of the kit was strictly 
followed. Briefly, A549 cells were seeded in the 6-well 
plates (25×104 cells per well). After incubation for 24h 
at 37°C, A549 cells were either treated (in a ratio of 1:1) 
with collected MSC treated supernatant from former stage. 
After 2 days, A549 cells were collected and washed twice 
with cold PBS, trypsinzed and pooled together. 5×105 
cells/mL of A549 cells was transferred to a tube and 
re-suspended in 100 μl of binding buffer. Then, 5 μl of 
FITC-conjugated Annexin V (Annexin V-FITC) and 5 
μl of propidium iodide (PI) were added, followed by 
incubation (15 min at room temperature in the dark room) 
and at last directly analyzed by flow cytometer (Calibur, 
Becton Dickinson). Therefore, the pro apoptotic cells were 
identified as Annexin V-FITC+ and PI−. The nonviable 
apoptotic cells were identified as Annexin V-FITC+ and 
PI+ , viable cells as Annexin V-FITC− and PI− and non-
apoptotic died cell as Annexin V-FITC- and PI+.
Statistical analysis
The experimental data were analyzed using SPSS 
statistical software (version 21.0) (SPSS Inc., Chicago, IL, 
Figure1. H NMR Spectrum of the Beta-Glucan 
Fraction of C. albicans
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Analysis of adipogenic and Osteogenic differentiation
Lipid vesicle accumulation in adipocytes differentiated 
from MSC was shown using oil red staining and the MSC 
adipogenic differentiation medium. The differentiated 
cells exhibit extensive intracellular lipid red vacuole 
formation typical of mature adipocytes. Alizarin Red S 
staining of extracellular calcium deposits was shown in 
mineralized MSC\derived mature osteoblasts (Figure 4).
Effect of β-glucan on the MSCs viability 
We tested a range of β-glucan concentrations to 
determine the optimal concentration for MSCs treatment. 
MTT assay showed that exposure of MSCs to 400, 800 
and 1,000 μg/ml of beta-glucan induced a significant 
decrease in cell viability (P<0.001). No significant 
changes in cell viability were observed at up to 25 μg/ml of 
beta-glucan (P>0.05). In addition, we found that β-glucan 
had a dose-dependent effect on MSCs proliferation. 
IC50 (concentration resulting in a 50% inhibition of cell 
growth) determine for different concentration of β-glucan. 
According findings IC50 for 1,000 μg/ml was 14%, for 
800μg/ml was 19%, for 400μg/mlwas 35%, and for 
200 μg/ml of β-glucan was 50%. The results showed 200 
μg/ml concentration of  beta-glucan determined as IC50 
whereas other examined concentration were toxic for 
MSC and led to cell death at 400, 800 and 1,000 μg/ml 
after 48 hours. Finally, 200 μg/ml of beta glucan was 
selected for MSC treatment and apoptosis assay in this 
study (Figure 5).
Cell apoptosis
To investigate how treated MSC supernatant (stored 
culture medium of MCSs treated with β (1,3) Glucan) 
effect on apoptosis of A549 cells  in vitro, FITC Annexin V 
Apoptosis Detection Kit  was employed to detect apoptotic 
cells. The result indicated that the presence of β-glucan in 
the supernatant of treated test groups induced a significant 
increase in A549 cancer cells apoptosis compared to the 
control group (without beta-glucan, (P-value= 0.00093)
(Figure 6).
Discussion
Several previous studies have shown that β-Glucans 
can serve as biological response modifiers and induce 
anti-tumor properties in vitro and in vivo (Geller et 
al., 2019; Gao et al.,2005; Choromanska et al., 2018). 
Remarkably, in recent years, for anti-cancer characteristic, 
β-Glucans are great of consideration worldwide, however, 
further clinical trials and experimental investigations are 
still needed (Petravić-Tominac et al., 2010; Mantovani et 
al., 2008). On the other hand, Mesenchymal stem cells are 
multi-potent progenitor adult stem cells exhibit numerous 
beneficial properties in treatment of various diseases and 
therapeutic potentials due to their immunomodulatory 
properties (Wang et al., 2018). Despite using conventional 
chemotherapy regimens and radiotherapy against cancer 
cells; because of emerging drug resistant stemness cells, 
relapses and metastasis, lung cancer treatment have 
been faced with many obstacles  in many developed and 
developing countries of the world. To overcome these 
challenges in the treatment of lung cancer, use of natural 
compounds and supplements like beta-glucan has received 
much attention for their beneficial properties (Rankin et 
al., 2018).
Until now, a few data are available concerning the 
effect of beta-glucan on lung cancer and MSC. For 
this reason, in the current study, we exploit the effect 
of β-glucans on MSCs and subsequently the possible 
anti-cancer property of β-glucans treated MSC supernatant 
was examined to suppress of lung cancer cells growth in 
Figure 2. The Morphological Feature of the MSC Cells 
in DMEM Medium (40x magnification, passage-3)
Figure 3. MSCs Surface Markers Expression were Analyzed by Flow Cytometry. "a shows CD90 , b shows CD105, c 
shows CD45 and d shows CD11-b" surface markers respectively.
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vitro for the first time. We tested a series of β-glucans 
concentrations to find out the optimal concentration of 
β-glucans. We found that 200 μg/ml of β-glucans is the 
optimal concentration and was used in further tests for 
MSC treatment. which was able to decrease of viability 
of MSC significantly. surprisingly, Larguech indicated 
that laminarin, a beta-(1 → 3)-D-glucan, suppressed 
MSC proliferation and their chondrogenic differentiation 
which propose potential applications in clinical MSC 
therapy (Larguech et al., 2018). The findings strongly 
supposed  that apoptosis of lung cancer cells was increased 
significantly in cells exposure to conditioned media of 
MSC treated with beta glucan in comparison to cells 
without treatments.
In agreement with our findings, Li et al., (2011) 
assessed the effect of hMSCs on lung cancer cell line 
A549 using a co-culture systems with mesenchymal stem 
cell supernatant (hMSCs-conditioned). They showed 
that hMSCs can inhibited tumor cells proliferation as 
compared to controls and increase the apoptosis of tumor 
cells. 
Similarity the beta glucan anti tumor activity, 
Interleukin-24(IL24) has been suggested as an effective 
anti-cancer agent. Zhang et al., (2013) evaluated the effects 
of MSCs-delivered IL24 on A549 cell proliferation and 
apoptosis. They observed that IL24-transduced UC-MSCs 
(IL24-MSCs) inhibited the growth of A549 lung cancer 
cells by induction of apoptosis and cell cycle arrest.
On the other hand, Murphy in another study expressed 
that the anti-bacterial effect of MSC is enhanced by the 
immunomostimulatory effect of beta-glucan and prevents 
acute lung injury due to infection (Murphy et al., 2017). 
The  mechan i sms  o f  immune-modu la to ry 
and anti-tumor effects of beta-glucan have been explained 
in many studies, with focus on the major anti-tumor effects 
of beta-glucan being due to the immune stimulating effects 
of beta-glucan. One of the important inhibitory cells 
in the tumor microenvironment is MSCs that produce 
inhibitory mediators and suppress immune responses 
Figure 4. A, Adipogenic Differentiation; B, Osteogenic Differentiation (100x magnification).
Figure 5. Viability Results of MSCs Treated with 
Different Concentration of β-glucan by MTT Test.
Figure 6. Flow Cytometry Results of the Annexin V-FITC and PI Staining for Apoptosis assay. The results of flow 
cytometry analysis showed that test group with MSCs supernatant treatment showed a significant increase of cell 
apoptosis (a) in comparison with the control group (b). P-value = 0.00093)
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(Wang et al., 2018). In this study, the conditioned medium 
of MSC treated with beta-glucan modulates MSCs and 
enhances the anti-cancer and apoptotic effect of MSC 
on lung cancer cells. These effects may be due to the 
change in the immunological phenotype of MSCs from 
immunosuppressive to immune-stimulatory, and this issue 
can be studied in other studies.
In conclusion, our findings suggest that, conditioned 
media of mesenchymal stem cells treated with β-glucans 
is capable of inhibiting lung cancer cell lines growth. 
Certainly a large number of studies are urgent necessity 
to evaluate the β-glucans effects and function for 
development of novel therapeutic approaches against 
cancer cells in the future. 
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